African Journal of Thoracic and Critical Care Medicine

Background. There is a paucity of evidence on the impact of mild COVID‐19 on the respiratory system, particularly in non‐healthcare‐ seeking individuals. Objectives. To investigate the effects of mild COVID‐19 on respiratory function and to identify indicators of decreased lung function. Methods. We conducted a cross‐sectional study in 175 non‐healthcare‐seeking individuals with confirmed acute SARS‐CoV‐2 infection who did not require hospitalisation. Participants were divided into three groups: those who had pulmonary function tests (PFTs) within 6 months, between 6 and 12 months, and between 12 and 24 months after infection. Each participant underwent spirometry, measurement of the diffusing capacity of the lungs for carbon monoxide (DLCO), a 6‐minute walking distance test (6MWD) and plethysmography. Results. The mean age of the participants was 44.3 years, and the mean body mass index (BMI) 32.7 kg/m2. Forty‐six participants had PFTs within 6 months, 64 between 6 and 12 months, and 65 between 12 and 24 months. Lower than expected DLCO was the most commonly detected abnormality (57%). Spirometry anomalies were noted in 23%, 10% showing an obstructive impairment and 13% a restrictive impairment, confirmed by a total lung capacity &lt;80%. An increased BMI was the only variable that was significantly and independently linearly associated with lower than predicted (&lt;80%) forced vital capacity, forced expiratory volume in the 1st second, DLCO and 6MWD. Conclusion. DLCO was low in a considerable proportion of non‐healthcare‐seeking individuals 2 years after mild COVID‐19. A high BMI was found to be significantly and independently associated with lower than predicted PFT results and 6MWD.

J Van Heerden

H Strijdom

A Parker

B W Allwood

U Lalla

C J Lombard

C F N Koegelenberg

The impact of mild COVID‐19 on medium‐term respiratory function

轻度COVID‐19对中期呼吸功能的影响

W Du Plessis

What is the cause of the reversed halo sign in this patient?

这个患者中反晕征的原因是什么？

Background. Connective tissue disease-associated interstitial lung disease (CTD-ILD) that progresses despite first-line immunosuppressive therapy is a clinical challenge. Rituximab (RTX) is a chimeric monoclonal antibody targeted to CD20+ B cells, resulting in B-cell depletion, and has been used as a salvage therapeutic modality in severe disease. Objectives. To investigate the therapeutic effects and safety of RTX in patients with severe CTD-ILD. Methods. A retrospective observational analysis of patients with severe CTD-ILD treated with salvage RTX therapy and various combinations of immunomodulatory therapy at Wits Donald Gordon Medical Centre, Johannesburg, South Africa, between January 2010 and December 2020 was performed. A total of 19 patients with progressive CTD-ILD, sufficient data, and 24-month follow-up were analysed. The effects of adding salvage RTX to standard drug therapy were investigated with serial pulmonary function testing, high-resolution computed tomography (HRCT) of the chest, and World Health Organization functional class (FC) assessment. Results. At 24-month follow-up from baseline, there was no significant deterioration in forced vital capacity (0.01 L; 95% CI –0.13 - 0.14) (p=0.91) after commencing RTX salvage therapy. Serial HRCT of the chest showed radiological disease stability or improvement in 13 of the 19 patients (68%). FC assessment showed no significant deterioration compared with baseline (p=0.083). No serious adverse drug reactions or deaths were recorded. Conclusion. Salvage RTX therapy, in combination with various immunomodulatory treatments, resulted in disease stability in the majority of patients with severe CTD-ILD over a 24-month period.

U F Seedat

B Christian

P E Boshoff

P Gaylard

G K Schleicher

Rituximab therapy in severe connective tissue disease- associated interstitial lung disease: A retrospective single-centre observational study

利妥昔单抗治疗重度结缔组织病相关间质性肺病的回顾性单中心观察性研究

M L Wong

The promise of rituximab in connective tissue disease-associated interstitial lung disease

利妥昔单抗在结缔组织病相关间质性肺疾病中的潜力

P Goussard

H Rabie

L Frigati

A Gie

S Irusen

C Jacobs

S Venkatakrishna

S Andronikou

Severe Mycoplasma pneumoniae infection in a young child: An emerging increase in incidence?

年轻儿童严重支原体肺炎感染：发病率是否正在上升？

涉及主题	医学内科学生物病理外科心理学精神科遗传学重症监护医学放射科免疫学哲学语言学
出版信息	出版商: South African Medical Association，出版周期: ，期刊类型: journal，开源期刊: 是
基本数据	创刊年份: 2018，原创研究文献占比: 0.00%，自引率:N.A.， Gold OA占比: 0.00%
期刊费用	$详情
平均审稿周期	24 weeks

African Journal of Thoracic and Critical Care Medicine

期刊引文格式

有 1 位以上作者的期刊

有 2 位作者的期刊

有 3 位作者的期刊

有 5 位以上作者的期刊

书籍引用格式

学位论文引用格式

网页引用格式

专利引用格式

手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS

投稿经验分享

The impact of mild COVID‐19 on medium‐term respiratory function

What is the cause of the reversed halo sign in this patient?

Rituximab therapy in severe connective tissue disease- associated interstitial lung disease: A retrospective single-centre observational study

The promise of rituximab in connective tissue disease-associated interstitial lung disease

Severe Mycoplasma pneumoniae infection in a young child: An emerging increase in incidence?

The impact of mild COVID‐19 on medium‐term respiratory function

What is the cause of the reversed halo sign in this patient?

Rituximab therapy in severe connective tissue disease- associated interstitial lung disease: A retrospective single-centre observational study

The promise of rituximab in connective tissue disease-associated interstitial lung disease

Severe Mycoplasma pneumoniae infection in a young child: An emerging increase in incidence?

ISSN	2617-0191, 2617-0205
h-index	5